Inside Mexico’s Regulatory Thought Process
A change in leadership at COFEPRIS, Mexico’s FDA equivalent, raises concerns about regulatory consistency and a tendency towards prohibition over regulation.Summary
The article discusses recent changes within Mexico’s healthcare regulatory landscape, specifically the unexpected replacement of Dr. Armida Zuñiga with Dr. Víctor Hugo Borja as head of COFEPRIS. The author expresses concern that this shift, coupled with a broader pattern of inconsistent policymaking and a preference for prohibition (illustrated by the vaping ban), threatens progress in areas like medical cannabis and overall public health. The author emphasizes the importance of regulatory stability, technical expertise, and trust between regulators, industry, and patients. They argue that abrupt changes and prohibitionist approaches undermine these crucial elements, leading to delayed treatments, thriving illegal markets, and ultimately, harm to the population. The piece advocates for data-driven, thoughtful reform and long-term institutional maturity to build a world-class regulatory environment in Mexico.
(Source：Mexico Business News)
